Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-907-1
CAS number: 111-78-4
no further results
The daily administration of the test item 1,5 -Cyclooctadien by oral
route to Wistar rats at nominal concentrations of 50, 150 and 450
mg/kg/day induced dose related clinical symptoms. The observation of the
animals was protocolled approximatley 1 or 2 hours after application
considering the peak period of the clinical symtoms. These symptoms
disappeared a few hours later and the animals showed nothing abnormal.
The predominant clinical symptom was lethargy sometimes associated with ataxia, abnormal gait, closed eyes
or piloerection. At the end of the treatment period animals of all dose
groups showed less or no clincal symptoms after application of the test
substance. During treatment period the high dose male and female group
showed a reduction in bodyweight and an increased food conversion rate
and an increase in relative liver weights. High dose females showed also
an increased relative kidney weight. In line with the increase in
relative liver weight hepatocellular hypertrophy was noted in high dose
male and females. The male and female medium dose group showed also
hepatocellular hypertrophy. All these findings were considered to be
For all the effects described evidence of reversibility was found after
two weeks without treatment. It is suggested that the reversible liver
changes observed are an expression of an adaptive response of the liver
to the test substance. As such, it is generally not considered as
adverse effect (Popp JA and Cattley RC (1991).
Therefore, in the experimental conditions of the study, the
no-observed-adverse-effect level (NOAEL) is 50 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again